1229922

Dutasteride

United States Pharmacopeia (USP) Reference Standard

• Synonym(s): (5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide
• Empirical Formula (Hill Notation): C₂₇H₃₀F₆N₂O₂
• CAS Number: 164656-23-9
• Molecular Weight: 528.53
• MDL number: MFCD00937869
• UNSPSC Code: 41116107
• PubChem Substance ID: 329749693
• NACRES: NA.24

Properties

• grade: pharmaceutical primary standard
• API family: dutasteride
• manufacturer/tradename: USP
• application(s): pharmaceutical (small molecule)
• format: neat
• storage temp.: 2-8°C
• SMILES string: O=C1C=C[C@@]2(C)[C@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4C(NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)=O)([H])N1
• InChI: 1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
• InChI key: JWJOTENAMICLJG-QWBYCMEYSA-N
• Gene Information: human ... SRD5A1(6715) , SRD5A2(6716) , SRD5A3(79644)

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

• Therapeutic Applications for Benign Prostatic Hyperplasia: Dutasteride, a potent 5-alpha-reductase inhibitor, is pivotal in developing plant-derived bioactive metabolites as alternatives for treating benign prostatic hyperplasia (BPH). This research highlights the potential of dutasteride in enhancing the efficacy and safety of prostate health treatments (Krishnamoorthi et al., 2024).


• Innovative Formulations for Hair Loss Treatment: Dutasteride is explored for its compatibility and efficacy in TrichoFoam, a natural vehicle for hair foams. This study demonstrates the potential of dutasteride in combination with other agents for treating androgenetic alopecia, providing a synergistic approach to hair loss management (Polonini et al., 2024).


• Impact on Sexual Dysfunction: The implications of dutasteride therapy for androgenetic alopecia on sexual dysfunction are critically analyzed. This global propensity-score-matched retrospective cohort study enhances our understanding of the side effects associated with long-term use of 5-alpha-reductase inhibitors (Lauck et al., 2024).


• Hormonal Background of Hair Loss: Dutasteride′s role is examined in the context of non-scarring alopecias, where hormonal imbalances play a significant part. This review discusses the hormonal mechanisms influenced by dutasteride, shedding light on its comprehensive effects in hair loss treatments (Owecka et al., 2024).


• Prostate Cancer Screening and Management: The effect of 5-alpha reductase inhibitors like dutasteride on the accuracy of prostate cancer detection through MRI is scrutinized. This research underscores the importance of understanding the pharmacological actions of dutasteride in improving diagnostic and management strategies for prostate cancer (Morote et al., 2024).

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable